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Abstract
Autoimmune hepatitis (AIH) is a chronic and progressive disease characterized by histologi-
cal interface hepatitis, hypergammaglobulinemia, and circulating autoantibodies. Multiple factors,
including molecular mimicry, a genetic background including major histocompatibility complex
class II, and defective function of regulatory T-cells, are involved in the pathogenesis. The di-
agnosis is made based on the scoring system of the International Autoimmune Hepatitis Group,
the sensitivity and specificity of which are90%, respectively. AIH is classified into 3 sub-types
based on the profiles of circulating autoantibodies: anti-nuclear antibody and/or smooth mus-
cle antibody-positive (type 1), anti-liver-kidney microsomal antibody-positive (type 2), and anti-
soluble liver antigen/liver-pancreas antigen antibody- positive (type 3). Recently, however, the
number of atypical cases lacking the usual features has increased-for example, patients with acute-
onset or fulminant-type AIH, autoantibody-negative patients, male patients, and patients with bile
duct injury-and thus the clinical features of AIH have been diversified. AIH is responsive to im-
munosuppressive treatment in most cases; however, relapse occurs in more than 80% of patients
within 1 year after immunosuppressive treatment withdrawal. The 10-year survival rate and the 10-
year hepatocellular carcinoma-free rate are90%, respectively, indicating that some patients reach
liver failure or develop hepatocellular carcinoma. To improve the prognosis of these patients,
persistent normalization of transaminase is required.
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utoimmune hepatitis (AIH),  ﬁrst reported by 
Waldenström in 1950 [1],  is a chronic and 
progressive disease characterized by histological inter-
face hepatitis,  hypergammaglobulinemia,  and circulat-
ing autoantibodies [2].  The prognosis of AIH is gen-
erally good with immunosuppressive treatment,  but 
some patients may develop hepatocellular carcinoma 
(HCC) or liver failure [3,  4].
　 There has been considerable uncertainty about the 
diagnostic criteria for AIH since identiﬁcation of the 
hepatitis C virus (HCV) in 1989 [5].  Anti-nuclear 
antibody (ANA),  anti-smooth muscle antibody (SMA),  
and anti-liver-kidney microsomal type 1 antibody 
(LKM-1),  which are important factors for the diagno-
sis of AIH,  are found in 9ｵ,  20ｵ,  and 6ｵ of 
chronic hepatitis C (CHC) cases,  respectively,  and the 
overall prevalence of autoantibodies is 30ｵ [6].  
Furthermore,  CHC patients with autoantibodies have 
more severe portal-periportal necroinﬂammation than 
those without autoantibodies [6].  To establish diag-
nostic criteria for AIH,  a scoring system was pro-
posed by the International Autoimmune Hepatitis 
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Group (IAHG) in 1993 [7].  The sensitivity of this 
scoring system was more than 90ｵ,  while the speci-
ﬁcity was insuﬃcient,  especially in patients with pri-
mary sclerosing cholangitis (PSC) [8],  so the scoring 
system was modiﬁed in 1999 [8].
　 Recently,  atypical cases lacking the usual features 
of AIH has also been reported [9ﾝ12],  with the result 
that the clinical features of AIH have been diversiﬁed.  
Herein,  we review the current status of autoimmune 
hepatitis.
Pathogenesis
　 A mechanism of molecular mimicry between foreign 
and self-antigens is considered to be one of the major 
sources of pathogenesis in AIH.  Several drugs (inﬂix-
imab,  minocycline,  atorvastatin,  hepatitis A vaccine) 
and viruses (hepatitis A virus,  hepatitis B virus,  
HCV,  Epstein-Barr virus) have been reported as pos-
sible triggers for AIH [13ﾝ20].  In the molecular 
mimicry theory,  self-reactive T cells,  initially acti-
vated by infectious pathogens,  subsequently provoke a 
self-destructive response in an organ expressing a 
cross-reactive self-Ag.  For example,  in patients with 
HCV infection,  molecular mimicry at the B cell level 
has been shown between CYP2D6,  which is an 
enzyme targeted by LKM-1 autoantibodies,  and the 
HCV NS3 and NS5a proteins [21].  On the other 
hand,  the development of AIH is associated with 
genetic background in patients with acute infection of 
hepatitis A virus and Epstein-Barr virus [20,  22].  
Defective suppressor-inducer T cell function may 
provoke helper T cell activation and antibody produc-
tion against asialoglycoprotein receptors (ASGPR) 
and thereby leading to the development of AIH type 1.
　 Genetic background is an important factor,  and 
individuals with certain major histocompatibility com-
plex (MHC) class II alleles are susceptible to AIH,  as 
in other autoimmune diseases.  MHC class II plays an 
important role in antigen presentation,  because pep-
tide antigens are recognized by CD4 T cells in asso-
ciation with MHC class II and types of peptides are 
determined by the amino acid sequence in the groove 
of MHC class II.  After exposure to foreign antigens,  
individuals with a certain MHC class II present spe-
ciﬁc peptides showing molecular mimicry to self anti-
gens,  and this may trigger an autoimmune reaction 
against self antigens.  For example,  certain amino acid 
residues of human leukocyte antigen (HLA)-DRｹ 
molecules (Lys71 in Caucasian patients with DRB1＊
0301 and DRB1＊0401 and Arg71 in Japanese patients 
with DRB1＊0405) have been reported to contribute to 
the susceptibility to AIH [23,  24].  This residue 71 
of the DRｹ molecule,  which is located on top of the ｸ
-helix pointing into the peptide-binding groove,  may 
inﬂuence peptide binding,  orientation,  and interaction 
with the T cell receptor.  However,  the types of self 
antigens presented by MHC class II in AIH type 1 
have not been clariﬁed.
　 It has recently been postulated that CD4＋ CD25＋ 
regulatory T cells play a role in the pathogenesis of 
AIH.  CD4＋ CD25＋ regulatory T cells maintain immu-
nological tolerance and suppress autoreactive immune 
responses.  A genetic or acquired defective function of 
regulatory T cells may cause excessive autoimmune 
reactions.  In patients with AIH,  CD4＋ CD25＋ regu-
latory T cells are numerically and functionally defec-
tive,  and the percentage of CD8＋ T cells spontane-
ously undergoing apoptosis is lower than in normal 
controls [25,  26].  Furthermore,  in patients with 
AIH,  Foxp3 expression in CD4＋ CD25＋ regulatory T 
cells is lower than in normal controls.  Circulating 
CD4＋ CD25＋ regulatory T cells increase during early 
pregnancy,  peaking during the second trimester and 
decreasing postpartum [27].  In contrast,  the activity 
of AIH declines during early pregnancy and ﬂares 
after delivery [28].  The inverse correlation between 
CD4＋ CD25＋ T cells and clinical activity may support 
the hypothesis that activation of autoreactive CD8＋ T 
cells under the condition of defective CD4＋ CD25＋ 
regulatory T cells may play a role in the pathogenesis 
of AIH.
Diagnosis
　 In Japan,  AIH has been diagnosed based on the 
criteria proposed by the Intractable Hepatitis Study 
Group of the Ministry of Health and Welfare of Japan 
(Japanese criteria) (Table 1) [29].  The criteria con-
sist of hypergammaglobulinemia (or IgG concentration
ｧ2.5g/dL),  circulating autoantibody (ANA- and/or 
SMA-positive),  histological features (plasma cell 
inﬁltration,  interface hepatitis,  and hepatocyte necro-
sis),  and exclusion of other known causes of chronic 
hepatitis (viruses,  alcohol,  drugs,  Wilsonʼs disease,  
hemochromatosis,  ｸ1-antitrypsin deﬁciency,  etc.).  
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Recently,  a revised IAHG scoring system was pro-
posed as a useful diagnostic tool in clinical practice 
(Table 2) [8].  Papamichalis et al.  [30] applied the 
scoring system to 423 patients with liver diseases 
excluding AIH and reported that the speciﬁcity was 
98ｵ.  In another study applying the scoring system to 
PSC patients,  the speciﬁcity was 93ｵ [31].  
Omagari et al.  [32] applied the scoring system to 89 
patients who fulﬁlled the Japanese criteria and 
reported that the sensitivity was 91ｵ.  The scoring 
system was also reported to be useful for pediatric 
patients with AIH [33].
　 The revised IAHG scoring system thus seems to be 
suﬃciently accurate for the diagnosis of AIH,  but 
there have been some diﬃculties in applying it to 
atypical forms of diseases.  Farias et al.  [34] 
reported that only 28ｵ of patients with antimitochon-
drial antibody (AMA)-positive AIH had scores high 
enough for a deﬁnite diagnosis.  On the other hand,  
Yatsuji et al.  [35] reported that,  in female patients 
with nonalcoholic fatty liver disease,  97ｵ had a score 
of 10 or more without including the liver biopsy 
results.  Furthermore,  Hayashi et al.  [36] reported 
that in the general Japanese population,  the rates of 
ANA-positive samples at 1: 40 and 1: 160 dilutions 
were 26ｵ and 10ｵ,  respectively,  with females hav-
ing a signiﬁcantly higher positive rate than males.  
These ﬁndings indicate that low titers of ANA may not 
be suﬃciently speciﬁc for a diagnosis of AIH,  and 
thus AIH diagnosis requires a liver biopsy.
　 Patients with AIH are classiﬁed into 3 sub-types 
based on proﬁles of circulating autoantibodies.  AIH 
type 1 is a classical type,  so-called lupoid hepatitis.  
It is associated with ANA and/or SMA.  In Japanese,  
it is dominantly associated with HLA-DRB1＊
0405; however,  DRB1＊0405 does not inﬂuence the 
clinical features [37].  In Caucasians,  AIH type 1 is 
primarily associated with DRB1＊0301 and second-
arily with DRB1＊0401 [38].  Patients with DRB1＊
0301 diﬀer from those with DRB1＊0401 in that they 
are younger and fail treatment more commonly [39].  
On the other hand,  DRB1＊0401 is associated with a 
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Table 1　 Criteria for diagnosis of autoimmune hepatitis in Japan. The Study Group of the Japanese Ministry of Health and Welfare 
(29).
General concept
Increased prevalence in younger females, chronic active hepatitis with potential progression to cirrhosis, existence of autoimmune mecha-
nisms in etiology, exclusion of all other known speciﬁc causes of chronic hepatitis, such as viruses, alcohol, drugs, etc. good response to 
corticosteroid therapy (typical).
Ｉ. Major ﬁndings
　1. Persistent elevation of serum aminotransferases
　2. Hypergammaglobulinemia of 2.5g/dL or greater (or IgG concentration of 2.5g/dL or greater)
　3. Circulating autoantibody: a) and/or b)
　　a) LE test-positive
　　b) ANA (antinuclear antibody)-positive and/or LE test-positive
　4. IgM anti-HAV (hepatitis A virus)-negative and absence of other evidence of HBV infection (HBs antigen-negative, anti-HBc antibody-
negative or at low titers)
　5. Absence of true-positive anti-HCV antibody or other evidence of HCV infection
II . Minor ﬁndings
　1. Systemic manifestations such as fever, arthralgia, and skin eruption
　2. Complications of other autoimmune diseases including collagen disease
　3. a) and/or b)
　　a) Accelerated ESR (erythrocyte sedimentation rate) at 30mm/h or faster
　　b) C-reactive protein (CRP)-positive
III. Histology
Chronic active hepatitis or cirrhosis with marked plasma cell inﬁltration and hepatocyte necrosis, absence of features of other speciﬁc 
diagnosis such as ｸ-1-antitrypsin deﬁciency
Diagnosis of autoimmune hepatitis
　1) Diagnostic: Fulﬁll all criteria of I and III
　2) Suggestive: Fulﬁll all criteria of I and at least one of II
　3) Possible: Fulﬁll all criteria of I
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lower frequency of death from liver failure or the need 
for transplantation.  
　 AIH type 2 is characterized by LKM-1 autoanti-
bodies and/or anti-liver cytosol antibody type 1 (LC1) 
[40].  The serum LC1 concentration,  at variance with 
that of LKM-1,  parallels liver disease activity [41].  
Recently,  the HLA-DQB1＊0201 allele was reported 
to be the primary genetic determinant of susceptibility 
to AIH type 2 [42].  The onset resembles acute viral 
hepatitis with marked elevation of transaminase and 
hypergammaglobulinemia [40].  Patients with AIH 
type 2 require prolonged treatment with corticoste-
roids and immunosuppressants.
　 AIH type 3 is characterized by the presence of 
antibody to soluble liver antigen/liver-pancreas anti-
gen (SLA/LP) [43].  Patients with AIH type 3 tend 
to have lower levels of transaminase,  gamma globulin,  
and bilirubin in comparison to patients with AIH type 
1 [44].  Response to immunosuppressive therapy is 
excellent,  but relapses occur frequently.
Atypical Forms of AIH
　 AIH predominantly aﬀects women,  and the clinical 
characteristics are diﬀerent between females and 
males.  Among Caucasian patients,  the male patients 
are distinguished from the females by lower frequen-
cies of concurrent autoimmune disease (17ｵ vs. 34ｵ) 
and HLA DR4 (24ｵ vs. 49ｵ) [45].  Treatment fail-
ure occurs more frequently in male patients only if 
they have HLA DR3.  Furthermore,  male patients 
experience relapse more frequently.  Among Japanese 
patients,  compared with females,  males have a lower 
frequency of deﬁnite diagnosis according to the 
revised scoring system and lower serum levels of 
immunoglobulin G [10].  However,  Japanese male and 
female AIH patients are similar in age,  form of clini-
cal onset,  symptomatic concurrent autoimmune dis-
ease,  and HLA-DR status.  The response to cortico-
steroid treatment is better in female patients than in 
males.
　 Recently,  reports on acute onset of AIH have 
increased,  and 26ｵ of Japanese patients have been 
reported to show acute onset [9].  Patients with acute 
onset have lower serum levels of albumin,  gamma 
globulin,  and immunoglobulin G,  and higher serum 
levels of total bilirubin,  AST,  and ALT,  and more 
frequently show moderate to severe lobular hepa-
titis; however,  acute onset reﬂects not only acute 
AIH but also acute exacerbation of pre-existing 
chronic disease.  On the other hand,  patients with 
acute liver failure have been reported occasionally.  
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Table 2　 Revised scoring system for autoimmune hepatitis.  
International Autoimmune Hepatitis Group (8).
Parameters/Features Score
Female sex ＋2
ALP: AST (or ALT) ratio:
　＜1.5 ＋2
　1.5ﾝ3.0 0
　＞3.0 －2
ANA, SMA or LKM-1
　＞1: 80 ＋3
　1: 80 ＋2
　1: 40 ＋1
　＜1: 40 0
AMA-positive －4
Hepatitis viral markers:
　Positive －3
　Negative ＋3
Drug history:
　Positive －4
　Negative ＋1
Average alcohol intake
　＜25g/day ＋2
　＞60g/day －2
Liver histology:
　Interface hepatitis ＋3
　Predominantly lymphoplasmacytic inﬁltrate ＋1
　Rosetting of liver cells ＋1
　None of the above －5
　Biliary changes －3
　Other changes －3
Other autoimmune disease ＋2
Optional additional parameters:
Seropositive for other deﬁned autoantibodies (perinu-
clear staining antineutrophil cytoplasmic antibody,  
anti-liver speciﬁc cytosolic antigen,  anti-soluble liver 
antigen,  anti-hepatic asialoglycoprotein receptor,  anti-
liver-pancreas antigen,  and anti-sulfatide)
＋2
　HLA DR3 or DR4 ＋1
　Response to therapy:
　　Complete ＋2
　　Relapse ＋3
Interpretation of aggregate scores:
　Pre-treatment:
　　Deﬁnite AIH ＞15
　　Probable AIH 10ﾝ15
　Post-treatment
　　Deﬁnite AIH ＞17
　　Probable AIH 12ﾝ17
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Corticosteroid treatment is of little beneﬁt to patients 
with acute liver failure,  and most of them require 
liver transplantation [46].  However,  low titer auto-
antibodies are frequently detected in cases of acute 
liver failure,  and the diagnosis of acute liver failure 
due to autoimmune hepatitis should be made carefully 
[47].
　 Bile duct injury,  which is characteristic of primary 
biliary cirrhosis (PBC),  is an important condition to 
consider in patients with AIH.  There has been one 
report of a patient with chronic nonsuppurative 
destructive cholangitis-like bile duct injuries who did 
not respond to ursodeoxycholic acid (UDCA) but did 
respond to prednisolone [48].  In one study,  bile duct 
injury was present in 24ｵ of patients negative for 
AMA,  and 7ｵ had destructive cholangitis [12].  
There are no diﬀerences in clinical characteristics,  
including response to immunosuppressive treatment,  
between patients with and without bile duct injury.  
Furthermore,  there is no diﬀerence in the concur-
rence of inﬂammatory bowel disease.  Recently,  10ｵ 
of AIH patients have been reported to have magnetic 
resonance cholangiography ﬁndings consistent with 
PSC [49].  It has been controversial whether these 
bile duct injuries are histological features of AIH or 
those of an overlap of AIH and PBC or PSC.
Clinical Features of Japanese AIH
　 In recent reports from Japan,  approximately 10ｵ 
of AIH patients were male,  and the peak incidence 
was between ages 50 and 60 years in both male and 
female patients.  Approximately 95ｵ of cases were 
positive for ANA and/or SMA [29,  50].  In a histo-
logical analysis,  85ｵ of patients showed interface 
hepatitis,  and rosetting of liver cells was seen in 28ｵ 
of cases [9].  In the same histological analysis,  zone 
III necrosis was seen in 29ｵ of cases,  and acute 
hepatitis and cirrhosis were diagnosed in 6ｵ and 
10ｵ of patients,  respectively,  at presentation [9]. 
Concurrent autoimmune diseases (autoimmune thy-
roiditis,  Gravesʼ disease,  Sjögrenʼs syndrome,  idio-
pathic thrombocytopenic purpura,  systemic lupus 
erythematosus,  rheumatoid arthritis,  autoimmune 
hemolytic anemia,  etc.) were found in 24ｵ of AIH 
patients [9].  Positivity for HLA-DR4 was seen in 
75ｵ of cases,  and there were no patients with DR3 
[29].  In other studies,  patients negative for DR4 
were mainly positive for DR2; however,  the fre-
quency of DR2 was similar between patients with AIH 
and healthy controls [37,  51].  These studies also 
demonstrated that the proportion of patients with DR4 
was low among patients aged＜30 years.  Inter-
estingly,  concurrence of thyroid disease (autoimmune 
thyroiditis,  Gravesʼ disease) is reported to be associ-
ated with DR4 [51].  There are some notable diﬀer-
ences in clinical features between Japanese and 
Caucasian patients with AIH (Table 3).  In Japanese 
patients compared with Caucasian patients,  propor-
tions of patients aged＜40 years,  male patients,  and 
patients with histological cirrhosis are smaller [29,  
52ﾝ55].  In Caucasian patients,  those with HLA DR3 
and DR4 are independently susceptible to autoimmune 
hepatitis [56],  while DR4 is predominant in Japanese 
patients and there are no Japanese patients with DR3 
[29].  Patients with DR3 have an earlier age of onset,  
and they deteriorate during corticosteroid treatment,  
die of liver failure,  and require liver transplantation 
more often than those with DR4 [39,  57].  Female 
patients have DR4 more frequently than do males 
221Autoimmune Hepatitis in JapanAugust 2008
Table 3　 Comparison of clinical features between Japanese patients and Caucasian patients with AIH type 1 (8,  10,  29,  45,  50ﾝ52,  
79ﾝ81).
Japanese patients Caucasian patients
Peak age at presentation 50ﾝ70 40ﾝ70
Male patients (%) 12ﾝ13 21ﾝ22
ANA positive (%) 84ﾝ95 72ﾝ79
SMA positive (%) 64 　 69ﾝ75
ANA and/or SMA positive (%) 95ﾝ99 97
Main HLA-DR (%) DR4 (70ﾝ75) DR3 (51ﾝ57),  DR4 (43ﾝ49)
Concurrent autoimmune disease (%) 24 　 30ﾝ31
 Autoimmune thyroiditis (%) 11 　 13ﾝ15
Cirrhosis at presentation (%) 10ﾝ12 27ﾝ34
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[45].  On the other hand,  patients with DR4 are older 
and respond better to corticosteroid treatment.  The 
diﬀerences in clinical features are considered to be due 
to the HLA-DR status.
Treatment
　 In the practice guidelines of the American Associa-
tion for the Study of Liver Diseases,  patients with 
serum AST levelsｧ10-fold the upper limit of normal 
or with serum ASTｧ5-fold the upper limit of normal 
in conjunction with a serum gamma globulin level at 
least twice the upper limit of normal are recommended 
for immunosuppressive treatment [58].  However,  to 
improve their prognosis,  persistent normalization of 
transaminase is required [3,  4].  Thus,  patients with 
abnormal levels of transaminase should receive some 
treatments.
　 In a study of Japanese patients,  normalization of 
ALT at 6 months after the introduction of initial 
treatment was achieved in 89ｵ of patients treated 
with corticosteroid,  100ｵ of patients treated with 
azathioprine,  and 51ｵ of patients treated with 
UDCA [29].  On the other hand,  in a study of 
Caucasian patients,  76ｵ of those without cirrhosis at 
presentation and 78ｵ of those with cirrhosis achieved 
remission by corticosteroid alone or a combination of 
corticosteroid and azathioprine [55].  Furthermore,  
the frequencies of patients who fail corticosteroid 
treatment are reported to be 7ﾝ14ｵ,  and onset at an 
early age,  acute presentation,  hyperbilirubinemia,  
and presence of HLA DRB1＊03 are associated with 
treatment failure [55,  59].  Together,  these ﬁndings 
indicate that Japanese patients show a favorable 
response to corticosteroid treatment compared with 
Caucasian patients.
　In a study by Montano-Loza et al.,  relapse is seen in 
86ｵ of AIH patients within 1 year after initial treat-
ment withdrawal [60].  Approximately 50ｵ of these 
patients relapse within 3 months.  Portal plasma cell 
inﬁltration in the liver biopsy specimens is predictive 
of relapse after drug withdrawal [61].  Serum levels 
of gamma globulin and immunoglobulin G are higher in 
patients with relapse compared with those with sus-
tained remission [62].  There is no diﬀerence in fre-
quencies of relapse after drug withdrawal between 
patients with and without cirrhosis at presentation.  
Patients should be treated to achieve normal serum 
levels of transaminase,  gamma globulin,  and immuno-
globulin G.  On the other hand,  patients who respond 
to initial corticosteroid treatment can achieve a sus-
tained remission after treatment withdrawal or after 
relapse and re-treatment [63].
　 Corticosteroid. In most patients,  prednisolone 
has been successfully used alone or in combination 
with azathioprine.  In Caucasian patients,  predniso-
lone is initially administered at a dose of 60mg daily 
or at a dose of 30mg daily in combination with aza-
thioprine at 50mg daily [58].  In Japanese patients,  
prednisolone monotherapy (30ﾝ40mg/day) or a combi-
nation of prednisolone (20ﾝ40mg daily) and azathio-
prine (50ﾝ100mg daily) is generally performed.  In 
Japanese patients with histological low-grade inﬂam-
matory activity,  prednisolone at 20mg daily may be 
suﬃcient [3,  4].  Prednisolone is tapered over 6ﾝ8 
weeks to 5ﾝ10mg daily and should be continued for at 
least 2 years after the achievement of the normaliza-
tion of transaminase [58].  Concerning the long-term 
side eﬀects of corticosteroid,  Seela et al.  [64] have 
reported that,  for a median follow-up of 13.5 years,  
weight gain,  cushingoid feature,  and steroid-related 
osteoporosis were seen in 21ｵ,  7ｵ,  and 5ｵ of 
patients,  respectively,  although none developed ste-
roid-induced diabetes.
　 Azathioprine. Azathioprine at 50mg daily is 
used in combination with prednisolone as an initial 
treatment [58].  In patients whose clinical,  labora-
tory,  or histological ﬁndings worsen despite conven-
tional treatment,  azathioprine at 150mg daily in 
combination with prednisolone is recommended [58].  
Furthermore,  Johnson et al.  [65] reported that,  
among patients who had achieved remission with a 
combination treatment of prednisolone and azathio-
prine and then continued to receive 2mg/kg azathio-
prine daily after withdrawal of prednisolone,  83ｵ 
remained in remission for a median follow-up of 67 
months.  The use of azathioprine during pregnancy is 
reported to be relatively safe [66,  67].  The side 
eﬀects of azathioprine include cholestatic hepatitis,  
veno-occlusive disease,  pancreatitis,  severe nausea,  
and bone marrow suppression.  Bone marrow suppres-
sion occurs more frequently in cirrhotic patients than 
non-cirrhotic patients [68,  69].
　 Ursodeoxycholic acid. UDCA treatment 
improves serum transaminase levels in patients with 
AIH type 1,  but changes of histological activity before 
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and after UDCA treatment have been controversial 
[70,  71].  Furthermore,  the duration from the intro-
duction of initial treatment to the normalization of 
serum ALT levels is longer in UDCA treatment com-
pared with corticosteroid treatment [52].  UDCA 
treatment should be performed in patients who are not 
candidates for corticosteroid treatment because of 
comorbidities such as osteoporosis and diabetes or 
patients with histological low-grade inﬂammatory 
activity and suﬃcient residual capacity of liver func-
tion.
　 Liver transplantation. Patients who fail 
immunosuppressive treatment proceed to hepatic fail-
ure and require liver transplantation.  The 5-year 
survival rate after liver transplantation has been 
reported to be 78ﾝ100ｵ [72ﾝ74].  However,  in 41ｵ 
of patients followed for more than 10 years after liver 
transplantation,  AIH has been reported to recur 
[75].
Prognosis
　 In patients with AIH type 1,  appropriate treatment 
improves histological ﬁbrosis,  even if cirrhosis is also 
present [76].  In Caucasians,  the prognosis of AIH 
type 1 has been reported to be similar to that of an 
age- and sex-matched cohort of disease-free controls 
from the general population [55].  The 10-year sur-
vival has been reported as 89ｵ and 90ｵ in Caucasian 
patients with and without cirrhosis at presentation,  
respectively.  Similarly,  the prognosis of Japanese 
patients with AIH type 1 is generally good with corti-
costeroid treatment.  The 10-year survival rate and 
the 10-year HCC-free rate have been reported as 
98ｵ and 93ｵ,  respectively [3].  On the other hand,  
the number of patients with AIH type 1 complicated by 
HCC has increased [77,  78].  Long-standing cirrhosis 
has been recognized as a risk factor for HCC develop-
ment.  The starting dose of corticosteroid (dose of 
prednisolone＜20mg/day),  relapse within 3 months 
after the normalization of serum ALT levels with 
initial treatment,  and elevated serum ALT levels dur-
ing the follow-up period (＞40IU/L) have all been 
signiﬁcantly correlated with progression of the dis-
ease [4].  In particular,  elevated serum ALT levels 
during the follow-up period are associated with HCC 
development and fatal outcome [3].  Thus,  the main-
tenance of normal serum ALT levels will improve 
patient prognosis.
Concluding Remarks
　 AIH is a chronic progressive liver disease caused 
by an autoimmune mechanism.  Although the precise 
mechanism remains to be fully clariﬁed,  multiple fac-
tors such as molecular mimicry,  a genetic background 
including HLA class II,  and defective regulatory T 
cell function are involved in the pathogenesis of AIH.  
Typical clinical features include histological interface 
hepatitis,  hypergammaglobulinemia,  and circulating 
autoantibodies,  but patients with atypical forms have 
been recognized and thus the clinical features have 
been diversiﬁed.  Immunosuppressive treatments 
including corticosteroid and/or azathioprine are eﬀec-
tive,  and the long-term prognosis is good.  UDCA is 
also eﬀective but needs further evaluation for the long-
term prognosis.  Liver transplantation is the indicated 
treatment for patients with hepatic failure,  though 
AIH recurs in 41ｵ of patients after liver transplan-
tation.
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